Zobrazit v EDS

Staphylococcus Aureus: Selective Reporting of Antibiogram Results and Its Impact on Antibiotic Use. Interventional Study with a Reference Group on the Effect of Switching from Non-Selective to Selective Antibiotic Reporting

Uloženo v:
Podrobná bibliografie
Název: Staphylococcus Aureus: Selective Reporting of Antibiogram Results and Its Impact on Antibiotic Use. Interventional Study with a Reference Group on the Effect of Switching from Non-Selective to Selective Antibiotic Reporting
Autoři: Franka Lestin-Bernstein, Ramona Harberg, Ingo Schumacher, Lutz Briedigkeit, Oliver Heese, Kristina Biedermann
Zdroj: Antimicrob Resist Infect Control
Antimicrobial Resistance and Infection Control, Vol 10, Iss 1, Pp 1-13 (2021)
Informace o vydavateli: Springer Science and Business Media LLC, 2020.
Rok vydání: 2020
Témata: Male, Staphylococcus aureus, Time Factors, Antimicrobial Stewardship/methods [MeSH], Female [MeSH], Staphylococcus aureus/drug effects [MeSH], Anti-Bacterial Agents/therapeutic use [MeSH], Aged [MeSH], Days of therapy (DOT), Humans [MeSH], Recommended daily dose (RDD), Electronic Health Records [MeSH], Tertiary Care Centers [MeSH], Selective reporting of susceptibility testing, Staphylococcal Infections/drug therapy [MeSH], Time Factors [MeSH], Anti-Bacterial Agents/administration, Selective antibiogram, Male [MeSH], Research, Anti-Bacterial Agents/pharmacology [MeSH], Germany [MeSH], Microbial Sensitivity Tests [MeSH], Antimicrobial stewardship (AMS), Infectious and parasitic diseases, RC109-216, Microbial Sensitivity Tests, Staphylococcus aureus infection, Tertiary Care Centers, Antimicrobial Stewardship, 03 medical and health sciences, 0302 clinical medicine, Germany, Electronic Health Records, Humans, Aged, Staphylococcal Infections, Anti-Bacterial Agents, 3. Good health, Female
Popis: Background:Antimicrobial stewardship (AMS) strategies worldwide focus on optimised antibiotic use. Selective susceptibility reporting is recommended as an effective AMS tool, although there is a lack of representative studies investigating the impact of selective susceptibility reporting on antibiotic use.The aim of this study was to investigate the impact of selective susceptibility reporting of Staphylococcus aureus (S. aureus) on antibiotic consumption. Enhancing the use of narrow-spectrum beta-lactam antibiotics such as flucloxacillin/cefazolin/cefalexin is one of the main goals in optimising antibiotic therapy of S. aureus infections.Methods:This interventional study with control group was conducted at a tertiary care hospital in Germany. During the one-year interventional period, susceptibility reports for all methicillin-sensitive S. aureus (MSSA) were restricted to flucloxacillin/cefazolin/oral cefalexin, trimethoprim-sulfamethoxazole, clindamycin, gentamicin and rifampin/fosfomycin; instead of reporting all tested antibiotics during the year before the intervention and in the reference clinic. The impact of the intervention was analysed by monitoring antibiotic consumption (recommended daily dose/100 occupied bed days: RDD/100 BD).Results:MSSA-antibiograms were reported for 2836 patients. Total use of narrow-spectrum beta-lactams more than doubled during the intervention (from 1.2 to 2.8 RDD/100 BD, PPS. aureus infections.Conclusions:As narrow-spectrum beta-lactams are not widely used for other infections, there is a strong indication that selective reporting guided clinicians to optimised antibiotic therapy of S. aureus infections.As useful AMS tool, we recommend implementing selective reporting rules into the national/international standards for susceptibility reporting.
Druh dokumentu: Article
Other literature type
ISSN: 2047-2994
DOI: 10.21203/rs.3.rs-41131/v1
DOI: 10.1186/s13756-021-01021-7
Přístupová URL adresa: https://europepmc.org/articles/pmc8572429?pdf=render
https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-01021-7
https://pubmed.ncbi.nlm.nih.gov/34742320
https://doaj.org/article/644482b2249c45259f538d95fac9a16b
https://aricjournal.biomedcentral.com/articles/10.1186/s13756-021-01021-7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572429/
https://repository.publisso.de/resource/frl:6464395
Rights: CC BY
Přístupové číslo: edsair.doi.dedup.....0bf8faeb05f88de12ec3e1f9c9a7b3e8
Databáze: OpenAIRE
Popis
Abstrakt:Background:Antimicrobial stewardship (AMS) strategies worldwide focus on optimised antibiotic use. Selective susceptibility reporting is recommended as an effective AMS tool, although there is a lack of representative studies investigating the impact of selective susceptibility reporting on antibiotic use.The aim of this study was to investigate the impact of selective susceptibility reporting of Staphylococcus aureus (S. aureus) on antibiotic consumption. Enhancing the use of narrow-spectrum beta-lactam antibiotics such as flucloxacillin/cefazolin/cefalexin is one of the main goals in optimising antibiotic therapy of S. aureus infections.Methods:This interventional study with control group was conducted at a tertiary care hospital in Germany. During the one-year interventional period, susceptibility reports for all methicillin-sensitive S. aureus (MSSA) were restricted to flucloxacillin/cefazolin/oral cefalexin, trimethoprim-sulfamethoxazole, clindamycin, gentamicin and rifampin/fosfomycin; instead of reporting all tested antibiotics during the year before the intervention and in the reference clinic. The impact of the intervention was analysed by monitoring antibiotic consumption (recommended daily dose/100 occupied bed days: RDD/100 BD).Results:MSSA-antibiograms were reported for 2836 patients. Total use of narrow-spectrum beta-lactams more than doubled during the intervention (from 1.2 to 2.8 RDD/100 BD, PPS. aureus infections.Conclusions:As narrow-spectrum beta-lactams are not widely used for other infections, there is a strong indication that selective reporting guided clinicians to optimised antibiotic therapy of S. aureus infections.As useful AMS tool, we recommend implementing selective reporting rules into the national/international standards for susceptibility reporting.
ISSN:20472994
DOI:10.21203/rs.3.rs-41131/v1